Hormonal manipulation of benign prostatic hyperplasia

Current Opinion in Urology

Volumn 23, Issue 1, 2013, Pages 17-24

  Rick, Ferenc G ^a,b   Saadat, Seyed H ^c   Szalontay, Luca ^a   Block, Norman L ^a,b,d   Kazzazi, Amir ^c   Djavan, Bob ^c   Schally, Andrew V ^a,b,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Division of Hematology/Oncology   (United States)

Author keywords

5 alpha reductase inhibitor; benign prostatic hyperplasia; gonadotropin releasing hormone; growth hormone releasing hormone; lower urinary tract symptoms; luteinizing hormone releasing hormone

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CETRORELIX; DOXAZOSIN; DUTASTERIDE; DUTASTERIDE PLUS TAMSULOSIN; FINASTERIDE; GONADORELIN ANTAGONIST; GROWTH HORMONE RELEASING HORMONE ANTAGONIST; HORMONE ANTAGONIST; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN THERAPY; ANTIINFLAMMATORY ACTIVITY; AZOOSPERMIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HAIR LOSS; HORMONAL REGULATION; HUMAN; HYPOGONADISM; INTERNATIONAL PROSTATE SYMPTOM SCORE; LEYDIG CELL TUMOR; MONOTHERAPY; NONHUMAN; OLIGOSPERMIA; ORGAN SIZE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SPERMATOZOON MOTILITY; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; COST-BENEFIT ANALYSIS; FINASTERIDE; GONADOTROPIN-RELEASING HORMONE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MALE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 84871198115     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835abd18     Document Type: Review

References (74)

1. Isaacs JT. Etiology of benign prostatic hyperplasia. Eur Urol 1994; 25 (Suppl. 1):6-9. (Pubitemid 23355406)
2. Lepor H, Kazzazi A, Djavan B. Alpha-blockers for benign prostatic hyperplasia: The new era. Curr Opin Urol 2012; 22:7-15.
3. Slater S, Dumas C, Bubley G. Dutasteride for the treatment of prostaterelated conditions. Expert Opin Drug Saf 2012; 11:325-330.
4. Lepor H. Medical treatment of benign prostatic hyperplasia. Rev Urol 2011; 13:20-33.
5. Roehrborn CG. Benign prostatic hyperplasia: An overview. Rev Urol 2005; 7 (Suppl. 9):S3YS14.
6. Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990; 17:461-475. (Pubitemid 20220190)
7. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: Age-related tissue-remodeling. Exp Gerontol 2005; 40:121-128. (Pubitemid 40343002)
8. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51:1202-1216. (Pubitemid 46436310)
9. Lin VK, Wang SY, Vazquez DV, et al. Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. Prostate 2007; 67:1265-1276. (Pubitemid 47435774)
10. Lucia MS, Lambert Jr. Growth factors in benign prostatic hyperplasia: Basic science implications. Curr Urol Rep 2008; 9:272-278.
11. Berger AP, Kofler K, Bektic J, et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003; 57:57-65. (Pubitemid 37070150)
12. Alonso-Magdalena P, Brossner C, Reiner A, et al. A role for epithelialmesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA 2009; 106:2859-2863.
13. Rick FG, Schally AV, Block NL, et al. LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71:736-747.
14. Rick FG, Schally AV, Block NL, et al. Antagonists of growth hormonereleasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 2011; 108:3755-3760.
15. Rick FG, Szalontay L, Schally AV, et al. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol 2012; 187:1498-1504.
16. Siejka A, Schally AV, Block NL, Barabutis N. Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormonereleasing hormone antagonist cetrorelix. BJU Int 2010; 106:1382-1388.
17. Siejka A, Schally AV, Block NL, Barabutis N. Antagonists of growth hormonereleasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate 2010; 70:1087-1093.
18. Sudduth SL, Koronkowski MJ. Finasteride: The first 5 alpha-reductase inhibitor. Pharmacotherapy 1993; 13:309-325; discussion 325-329.
19. Djavan B, Handl MJ, Dianat S. Combined medical treatment using dutasteride and tamsulosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Expert Opin Pharmacother 2010; 11:2535-2547.
20. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387-2398. (Pubitemid 37542987)
21. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123-131.
22. Haillot O, Fraga A, Maciukiewicz P, et al. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer Prostatic Dis 2011; 14:302-306.
23. Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol 2012; 187:1732-1738.
24. Schmidt LJ, Tindall DJ. Steroid 5 a-reductase inhibitors targeting BPH and prostate cancer. J Steroid Biochem Mol Biol 2011; 125:32-38.
25. Oelke M, Bachmann A, Descazeaud A, et al. members of the European Association of Urology (EAU) Guidelines Office. Guidelines on Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). In: EAU Guidelines, edition presented at the 27th EAU Annual Congress, Paris 2012. ISBN 978-90-79754-83-0. 2012.
26. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185:1793-1803.
27. Issa MM, Runken MC, Grogg AL, Shah MB. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: Dutasteride versus finasteride. Am J Manag Care 2007; 13 (Suppl. 1):S10YS16.
28. Parsons JK, Schenk JM, Arnold KB, et al. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol 2012; 62:234-241.
29. Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108:388-394.
30. Kaplan SA. Re: Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: The Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108:388-394.
31. Montorsi F, Roehrborn C, Garcia-penit J, et al. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) s. BJU Int 2011; 107:1426-1431.
32. Roehrborn CG, Barkin J, Siami P, et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind combination of avodart and tamsulosin. BJU Int 2011; 107:946-954.
33. Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: A model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int 2012; 109:731-738.
34. Nickel JC, Barkin J, Koch C, et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J 2008; 2:16-21.
35. Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: A randomised controlled study. Aging Male 2011; 14:53-58.
36. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536-2559.
37. Page ST, Hirano L, Gilchriest J, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 2011; 186:191-197.
38. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349:215-224. (Pubitemid 36859473)
39. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192-1202.
40. Tindall DJ, Rittmaster RS. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol 2008; 179:1235-1242.
41. Hsieh J-T, Chen S-C, Yu H-J, Chang H-C. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: Implications for chemoprevention of prostate cancer. Prostate 2011; 71:1115-1121.
42. Marberger M, Freedland SJ, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: Lessons from the REDUCE study. BJU Int 2012; 109:1162-1169.
43. Roehrborn CG, Andriole GL, Wilson TH, et al. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011; 59:244-249.
44. Berthold D, Lhermitte B, Uffer M, Doerfler A. Finasteride-related Leydig cell tumour: Report of a case and literature review. Andrologia 2012; 44 (Suppl. 1):836-837.
45. Prahalada S, Majka JA, Soper KA, et al. Leydig cell hyperplasia and adenomas in mice treated with finasteride, a 5 alpha-reductase inhibitor: A possible mechanism. Fundam Appl Toxicol 1994; 22:211-219. (Pubitemid 24089166)
46. Garcia PV, Barbieri MF, Perobelli JE, et al. Morphometric-stereological and functional epididymal alterations and a decrease in fertility in rats treated with finasteride and after a 30-day posttreatment recovery period. Fertil Steril 2012; 97:1444-1451.
47. Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: A report of two cases. Fertil Steril 2008; 90:849 e17-849 e19.
48. Tu HYV, Zini A. Finasteride-induced secondary infertility associated with sperm DNA damage. Fertil Steril 2011; 95:2125 e13-2125 e14.
49. Aggarwal S, Thareja S, Bhardwaj TR, Kumar M. 3D-QSAR studies on unsaturated 4-azasteroids as human 5alpha-reductase inhibitors: A self organizing molecular field analysis approach. Eur J Med Chem 2010; 45:476-481.
50. Aggarwal S, Thareja S, Verma A, et al. An overview on 5alpha-reductase inhibitors. Steroids 2010; 75:109-153.
51. Aubry S, Aubert G, Cresteil T, Crich D. Synthesis and biological investigation of the b-thiolactone and b-lactam analogs of tetrahydrolipstatin. Org Biomol Chem 2012; 10:2629-2632.
52. GarridoM, Bratoeff E, Bonilla D, et al. New steroidal lactones as 5a-reductase inhibitors and antagonists for the androgen receptor. J Steroid Biochem Mol Biol 2011; 127:367-373.
53. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, et al. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994; 24:84-92. (Pubitemid 24073107)
54. Comaru-Schally AM, Brannan W, Schally AV, et al. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 1998; 83:3826-3831. (Pubitemid 28513557)
55. Debruyne F, Gres AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008; 54:170-177.
56. Debruyne F, Tzvetkov M, Altarac S, Geavlete PA. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 2010; 76:927-933.
57. Gonzalez-Barcena D, Vadillo Buenfil M, Garcia Procel E, et al. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormonereleasing hormone, Cetrorelix (SB-75). Eur J Endocrinol 1994; 131:286-292. (Pubitemid 24297519)
58. Horvath JE, Toller GL, Schally AV, et al. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proc Natl Acad Sci USA 2004; 101:4996-5001. (Pubitemid 38469191)
59. Kramer G, Steiner GE, Handisurya A, et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate 2002; 52:43-58. (Pubitemid 34553191)
60. Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008; 54:1379-1384.
61. Steiner GE, Newman ME, Paikl D, et al. Expression and function of proinflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 2003; 56:171-182. (Pubitemid 36918167)
62. Djavan B, Eckersberger E, Espinosa G, et al. Complex mechanisms in prostatic inflammatory response. Eur Urol Suppl 2009; 8:872-878.
63. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate 2004; 58:121-129. (Pubitemid 38160899)
64. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4:33-43. (Pubitemid 350291102)
65. Westley BR, May FE. Insulin-like growth factors: The unrecognised oncogenes. Br J Cancer 1995; 72:1065-1066.
66. Chopin LK, Herington AC. A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate 2001; 49:116-121. (Pubitemid 32937807)
67. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008; 40:315-322. (Pubitemid 351859442)
68. Letsch M, Schally AV, Busto R, et al. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 2003; 100:1250-1255. (Pubitemid 36183988)
69. Heinrich E, Schally AV, Buchholz S, et al. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapywithGHRHantagonistMZ-J-7-138. Prostate 2008; 68:1763-1772.
70. Stangelberger A, Schally AV, Rick FG, et al. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate 2012; 72:555-565.
71. Rick FG, Schally AV, Szalontay L, et al. Antagonists of growth hormonereleasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA 2012; 109:1655-1660.
72. Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83:1131-1146. (Pubitemid 37013048)
73. Clyn M. BPH: Hormone antagonists for two-pronged attack on BPH. Nat Rev Urol 2012; 9:235.
74. Hubert RS, Vivanco I, Chen E, et al. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 1999; 96:14523-14528. (Pubitemid 30000683)